Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
16/NE/0279	198051	HRA Approval	TIDAL: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)	No		07/12/2017	21/12/2017	29/09/2016	14/02/2018	15/01/2018	15/02/2018	sub-contract delays from partner Trust	Neither
17/LO/1875	219487	HRA Approval	RAMPART: Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage multi-centre randomised-controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.	No		10/11/2017	10/11/2017	03/11/2017				Project still in set-up. Initial delay in awaiting PI capacity - study still in set-up	NHS Provider
17/LO/1869	230951	HRA Approval	TULIP :A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer	No		19/11/2017	19/11/2017	16/01/2018	14/09/2018	26/09/2018		Awaiting activation	NHS Provider
17/NE/0366	235534	HRA Approval	SEPCELL: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of Cx611 expanded allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with a severe community-acquired bacterial pneumonia and admitted to the intensive care unit. SEPCELL study.	No		05/12/2017	15/12/2017					sub-contract delays from partner Trust	Neither
18/NE/0005	236687	HRA Approval	AMG 678: Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials	Yes	11/09/2018	08/01/2018	08/01/2018	15/02/2018	01/06/2018	20/06/2018	11/07/2018	Internal capacity issues by support service	NHS Provider
18/SC/0015	236685	HRA Approval	ACZ885: A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)	No		21/12/2017	08/01/2018	23/02/2018	25/05/2018	12/06/2018	02/08/2018	Complicated patient pathway and change over of nursing staff	NHS Provider
14/SC/1346	151280	HRA Approval	National Lung Matrix Trial: Multi-drug,geneticmarker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer	No		12/01/2018	12/01/2018	15/07/2017				sub-contract delays from partner Trust - study in set-up	Neither
17/EM/0338	229242	HRA Approval	ABL001: A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	No		28/07/2017	26/01/2018	31/01/2018	02/07/2018	09/07/2018	03/08/2018	Sub-contracting delays with partner Trust	Neither
17/SC/0661	227234	HRA Approval	CYTOFLOC: Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for post chemo-radiotherapy surveillance in patients with oesophageal cancer ? a feasibility study	No		18/12/2017	26/01/2018	23/01/2018	28/08/2018	17/08/2018		Awaiting activation - Awaiting activation ? Sponsor delay for activation	Sponsor
17/NW/0634	209375	HRA Approval	COMICE: A randomized double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer.	No		29/01/2018	29/01/2018	16/01/2018	21/09/2018	21/09/2018	25/09/2018	Delays in study set-up by CTU	Neither

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
14/NE/1240	163350	HRA Approval	PFIZER B1371012: A RANDOMIZED, DOUBLE-BLIND PHASE 1B/2 STUDY OF PF-04449913 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED INTERMEDIATE-2 OR HIGH-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA WITH 20-30% BLASTS AND MULTI-LINEAGE DYSPLASIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA	No		03/02/2018	03/02/2018	06/03/2018	07/09/2018	13/09/2018		Awaiting activation - sub-contract delays with partner Trust	Neither
18/LO/0651	240503	HRA Approval	BAYER 17403: A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	Yes	01/09/2018	08/02/2018	08/02/2018	13/06/2018	19/06/2018	23/07/2018	23/08/2018	Awaiting ARSAC Licence approval	NHS Provider
18/NW/0031	230387	HRA Approval	net-02: A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (NEC)	No		12/02/2018	12/02/2018	18/02/2018				Study in set-up - not open	Neither
17/YH/0187	218853	HRA Approval	PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma	Yes	03/10/2018	22/02/2018	22/02/2018	11/10/2017	22/06/2018	05/06/2018	27/09/2018	Sponsor delay in signing CTA and arranging SIV	Sponsor
17/WA/0111	225522	HRA Approval	HATCY: A Phase III, multicenter, randomised controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study)	No		25/09/2017	02/03/2018					Study in set-up - not open	Neither
15/SC/0103	154496	HRA Approval	SCALOP 2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer	No		14/02/2018	31/03/2018	26/07/2016				Study in set-up - not open	Neither
16/WM/0501	185601	HRA Approval	WISTERIA: A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer	No		08/02/2018	08/02/2018	28/02/2017	11/04/2018	29/03/2018	19/04/2018	complicated phase I pathway, complex contracting and finance negotiations	Both
14/EM/1172	146009	HRA Approval	Cambridge Brain Mets Trial 1: A proof? of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low?-dose, targeted radiotherapy	No		30/06/2016	13/11/2017	26/07/2016	20/05/2016	13/06/2017	27/04/2018	Awaited the Phase I element of the study to finish before entering the study at next Phase: Sponsor put study on temporary halt for several months.	Both

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
17/LO/1289	226881	HRA Approval	UNITY UTX TGR 205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin?s Lymphoma.	No		16/11/2017	20/12/2017	17/10/2017	21/05/2018	17/05/2018	01/06/2018	Sub-contracting delays with partner Trust	Neither
17/WS/0180	225790	HRA Approval	OREO: A Phase 111b, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)	No		13/09/2017	12/10/2017	02/02/2018	20/04/2018	22/05/2018	08/06/2018	Complex and protracted contract and financial negotiations : staff capacity issues	Sponsor
16/LO/0422	198606	HRA Approval	SIERRA-2: A Phase I Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer	No		21/09/2017	27/11/2017	23/05/2016	13/06/2018	09/07/2018		Awaiting activation ? delays due to sub-contracting with partner Trusts & ARSAC licence approval	Neither
16/LO/0423	198451	HRA Approval	SIERRA-1: A Phase I trial of SRA737 (a CHK1 inhibitor) administered orally in subjects with advanced cancer	No		21/09/2017	24/11/2017	19/05/2016	05/06/2018	09/07/2018		Awaiting activation ? delays due to sub-contracting with partner Trusts & ARSAC licence approval	Neither
17/EM/0166	222665	HRA Approval	AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)	No		29/03/2018	29/03/2018	30/06/2017				Study still in set-up - Not open	Neither
15/WS/0011	122822	HRA Approval	BALLAD: A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI-002)	No		31/10/2017	31/10/2017	29/04/2016	26/02/2018	08/02/2018	24/08/2018	Internal capacity issues	NHS Provider
17/NW/0330	222996	HRA Approval	AGIOS AG120-C-005 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation	Yes	13/09/2018	21/09/2017	21/10/2017	16/10/2017	05/04/2018	05/07/2018	20/07/2018	Internal capacity issues by support service: complicated contract & financial negotiations: ARSAC Licence approval.	Both
16/YH/0157	204585	HRA Approval	PLATO?-?PersonaLising?Anal?cancer?radioTherapy?dOse?-?Incorporating?Anal?Cancer?Trials?(ACT)?ACT3,?ACT4?and ACT5	No		03/04/2017	03/10/2017	20/07/2016	07/09/2018	28/08/2018	14/09/2018	RTTQA approval and ARSAC Licence approval delays	Both
18/NE/0136	240494	HRA Approval	CheckMate 9DX- 0078/1587: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	No		01/02/2018	04/05/2018	13/07/2018	08/08/2018	28/08/2018	28/09/2018	Delays with financial negotiations and sub-contract queries with partner Trust	Both
18/WS/0023	235821	HRA Approval	CA2099TM _ 00781586_SCCHN BMS: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)	No		14/05/2018	14/05/2018					Study closed by Sponsor whilst still in set-up at CCC.	Sponsor
18/EM/0147	238388	HRA Approval	ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma	No		18/05/2018	11/06/2018	16/05/2018				Study not open - still in set-up	Neither

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
18/NW/0424	242807	HRA Approval	BEIGENE AME ? BGB?290-106: A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Pamiparib following Single Oral Dose Administration in Patients with Advanced and/or Metastatic Solid Tumors	No		01/08/2018	01/08/2018					Study not open - still in set-up	Neither
14/WS/1096	149204	HRA Approval	PARADIGM OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study.	No		09/08/2017	09/10/2017	16/06/2017	28/06/2018	09/07/2018		Awaiting activation ? delay due to the completion of the Phase I element of the study to be conducted as CCC taking part in Phase II only.	Neither
17/NE/0234	228388	HRA Approval	KEYNOTE 629: A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)	Yes	09/07/2018	19/07/2017	19/10/2017	29/08/2017	01/12/2017	13/12/2017	01/02/2018	Sponsor delay - considerable sponsor contract and costing delays	Sponsor
17/LO/2024	231946	HRA Approval	LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations	No		31/08/2017	31/10/2017	14/02/2018	03/09/2018	24/09/2018		Delay due to patient pathway confirmation from PI - awaiting activation	NHS Provider
12/LO/0515	95626	HRA Approval	OPTIMA: Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis	No		07/09/2017	07/10/2017	03/08/2016				Awaiting study documentation from internal service departments - study still in set-up	NHS Provider
14/WM/1170	161147	HRA Approval	COMPARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer	No		22/01/2016	22/10/2017	23/05/2016	29/06/2018	05/06/2018	06/09/2018	Delays in 2 site opening for a complex study	Neither
17/LO/0023	215490	HRA Approval	MUK nine b: OPTIMUM. A phase II study evaluating optimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia.	No		15/08/2017	15/10/2017	30/03/2017	14/09/2018	16/08/2018		Study in set-up: Dependent on MUK 9 opening, 9B has subcontracting delays with partner Trust	Neither
17/SC/0090	215068	HRA Approval	c-TRAK TN: A randomised trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer	No		19/06/2017	08/10/2017	22/06/2018	09/10/2018	01/10/2018		Awaiting activation ? delays due to sub-contract with partner Trust, PI delays	Neither
17/SC/0314	225425	HRA Approval	REPLIMUNE: An Open-Label, Multicenter, Phase 1/2 Study of RPI as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors	No		16/08/2017	29/10/2017	30/08/2017	13/07/2018	23/08/2018		Awaiting activation ? delays due to complex financial negotiations and confirmation from Gene Therapy Safety Committee	Both
14/NI/1037	156193	HRA Approval	LYMRIT: A phase I/II study of 177Lu-HH1 (Betalutin?) radioimmunotherapy for treatment of relapsed CD37+ non-Hodgkin lymphoma	No		25/04/2018	25/04/2018					Study in set-up	Neither
15/EM/0440	178108	HRA Approval	AZTEC: A?phase?II?study?of?the?use?of?azacitidine?for?the?treatment?of?patientswith chronic graft?versus?host?disease who?have?failed therapy with corticosteroids	No		09/08/2017	04/04/2018	09/08/2016				Study in set-up	Neither

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
16/EM/0380	198726	HRA Approval	STUDY 15: A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine	No		12/07/2018	12/07/2018	09/11/2016				Study in set-up	Neither
17/EM/0440	230556	HRA Approval	DANTE: A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma	No		23/04/2018	05/06/2018	18/01/2018	12/09/2018	28/08/2018		Study in set-up	Neither
17/LO/0980	219505	HRA Approval	HALT - Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours	No		19/03/2018	30/05/2018	10/07/2017				Study in set-up	Neither
17/SC/0536	216069	HRA Approval	COPELIA: A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometrial Carcinoma or for disease relapse within 12 months of adjuvant carboplatin-paclitaxel chemotherapy.	No		05/12/2017	10/05/2018					Study in set-up	Neither
18/EM/0112	236871	HRA Approval	ALL-RIC: A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.	No		21/06/2018	21/06/2018	12/06/2018				Study in set-up	Neither
18/LO/0515	236848	HRA Approval	POLARIS : Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma	No		28/06/2018	28/06/2018	27/07/2018				Study in set-up	Neither
18/NE/0077	235979	HRA Approval	PORT: Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphoma	No		16/07/2018	16/07/2018	31/05/2018				Study in set-up	Neither
18/NW/0290	226529	HRA Approval	FORMA 2102-HEM-101 PH2: A Phase 1/2, Multicenter, Open-label, Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 R132 Mutation	No		13/04/2018	30/05/2018	20/06/2018				Study in set-up	Neither